OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cardiology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Three different therapies to target PCSK9	644
Bariatric metabolic surgery more effective than GLP1R agonists in preventing congestive HF	576
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction	476
Antibody treatment to deplete transthyretin amyloid deposits in the heart	435
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40%	389
LIPC variant in combined hypocholesterolaemia	338
Intravascular imaging improves outcomes	295
Injectable and conductive cardiac patch	270
Basophils promote healing after MI	263
Travelling with heart failure: risk assessment and practical recommendations	249
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	240
Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease	239
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals	233
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	229
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	219
Genetics and mechanisms of thoracic aortic disease	219
Abbreviating DAPT reduces the risk of bleeding	199
Alternative defibrillation strategies improve outcomes	198
Heterogeneity of the post-infarct epicardium	193
Defining iron deficiency in patients with heart failure	190
Detection of subclinical hypertrophic cardiomyopathy	190
Electron microscopy of cardiac 3D nanodynamics: form, function, future	189
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization	179
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	179
Hallmarks of cardiovascular ageing	165

PPAR control of metabolism and cardiovascular functions	158
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	158
Neuromodulation reduces inflammation in HFpEF	154
A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice	151
Graded exercise therapy should not be recommended for patients with post-exertional malaise	148
Decongestion in heart failure: medical and device therapies	144
Extracellular matrix in vascular homeostasis and disease	144
Colchicine in acute coronary syndromes: the present and the possible future	137
Increased degradation of desmosomal proteins in ACM	134
Preparticipation screening reduces SCD in young athletes	134
CSDE1 regulates LDL receptor levels	131
Catheter ablation improves outcomes in patients with AF and end-stage HF	129
No benefit of apoA-I infusion after myocardial infarction	123
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk	122
LDL-cholesterol lowering with obicetrapib	116
Targeting immune cell recruitment in atherosclerosis	114
The oral microbiome in the pathophysiology of cardiovascular disease	112
Genomic enhancers in cardiac development and disease	110
Reactive oxygen species in hypertension	109
Prevention of atherosclerosis from childhood	103
Increasing representation and diversity in cardiovascular clinical trial populations	103
Treatment of mild chronic hypertension in pregnancy reduces pre-eclampsia risk	102
Semaglutide is beneficial in patients with HFpEF and obesity	100
RNA interference lowers triglyceride levels	98
Modelling pre-eclampsia and its cardiovascular effects	94
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials	93
Reply to ‘Graded exercise therapy should not be recommended for patients with post-exertional malaise’	93
Bempedoic acid prevents cardiovascular events in statin-intolerant patients	88
Donor macrophages influence rejection of transplanted hearts	88
Unlocking excellence in health care: the power of inclusive and sensitive language in medicine	86
Cardiac sarcomere turnover by unidirectional replacement of proteins	86
Promising novel siRNA for the treatment of hypertension	82
Evidence does not support the reduction of added sugar intake from all food sources	82
BP management with a village-doctor-led strategy	81
Global epidemiology of heart failure	81
Single-cell profiles of CHD and CM	76
An epigenome editing approach induces durable silencing of Pcsk9	75
CV benefits of finerenone in T2DM and CKD	74
Computational modelling of cardiovascular pathophysiology to risk stratify commercial spaceflight	71
Author Correction: The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	70
Novel factor XIa inhibitor reduces bleeding compared with apixaban in atrial fibrillation	69
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms	69
The role of the molecular autopsy in sudden cardiac death in young individuals	68
Development of a miniature, bioresorbable, light-activated pacemaker	68
Efferocytosis in atherosclerosis	67
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	67
Heart transplantation: advances in expanding the donor pool and xenotransplantation	65
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target	65
Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy	64
New insights into dietary cholesterol absorption	64

CNR1 antagonism attenuates cannabis-induced atherosclerosis	64
Gut bacteria can break down cholesterol	61
Low alcohol intake might lower CVD risk by reducing stress-related brain activity	61
A call for training programmes in cardiovascular genomics	61
Renal denervation for hypertension	59
Cardiovascular benefits of fermented foods and beverages: still up for debate	58
Cardiovascular disease and cancer: shared risk factors and mechanisms	57
Molecular gatekeepers of endogenous adult mammalian cardiomyocyte proliferation	57
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	56
Phenotyping atherosclerotic plaque and perivascular adipose tissue: signalling pathways and clinical biomarkers in atherosclerosis	56
Improving medication adherence in cardiovascular disease	55
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis	55
Social disparities in COVID-19 prevention	55
Mechanisms and treatment of pulmonary arterial hypertension	55
Pacing with respiratory sinus arrhythmia improves outcomes in heart failure	52
Publisher Correction: Cardiac involvement in the long-term implications of COVID-19	50
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	49
Cardiac optogenetics: controlling the heart with light	48
Epigenetic editing in cardiovascular medicine: moving beyond the hype	47
RNA-based therapies targeting APOC3 lower triglyceride levels in patients with hypertriglyceridaemia	47
The need for increased pragmatism in cardiovascular clinical trials	46
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention	45
Blood pressure and its variability: classic and novel measurement techniques	44
A fresh look at coronary microembolization	43
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications	43
The cardiac parasympathetic system has two parallel circuits	42
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	42
Inhibiting aldosterone synthase reduces blood pressure	41
Age-induced senescence impairs the neurovascular interface in the heart	40
Combined measure of inflammation, cholesterol and lipoprotein(a) predicts 30-year cardiovascular risk in women	39
Black In Cardio: promoting diversity and representation in the cardiovascular field	37
Boosting mitochondrial metabolism with dietary supplements in heart failure	37
Sotatercept as add-on therapy for advanced PAH	36
Phase separation of protein kinase A: a new paradigm in cardiac regulation?	36
Gout flares can precede cardiovascular events	36
Tracing the roots of cardiac fibrosis: role of endothelial-to-mesenchymal transition	35
ASGR1 inhibition stimulates cholesterol excretion	34
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	34
Consequences of ionizing radiation exposure to the cardiovascular system	33
Trials and tribulations of cell therapy for heart failure: an update on ongoing trials	31
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	31
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	30
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	30
Surgery safer than endovascular therapy for CLTI	28
Genome editing prevents hypertrophic cardiomyopathy in mice	27
A distinct platelet differentiation pathway is involved in age-related thrombocytosis	27
Imaging cAMP nanodomains in human iPSC-derived cardiomyocytes	26
Benefit of early aortic valve surgery in asymptomatic, severe AS	26
Publisher Correction: Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	25
Characterization of the F8 gene: a silver lining in a dark cloud	24
Preserving the future of heart transplantation	24
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	23
Effects of lifestyle factors on leukocytes in cardiovascular health and disease	23
A role for lipophagy in atherosclerosis	23
Alain Cribier (1945–2024)	21
High troponin I levels predict death after surgery	21
Unravelling the genetic heart–brain connection using MRI	21
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	21
Posterior left pericardiotomy reduces AF incidence after cardiac surgery	21
Implementing LGBTQ-inclusive policies for cardiology practice and the workforce	20
Finerenone prevents atrial fibrillation in patients with CKD and diabetes	20
Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity	18
Charting the future of cardiology with large language model artificial intelligence	18
Sustained BP reduction with renal denervation	18
Mind the gap: sex-related differences in cardiovascular disease	18
Contemporary pharmacological treatment and management of heart failure	17
Extracellular vesicles in cardiovascular homeostasis and disease: potential role in diagnosis and therapy	17
Mapping the functions of IgM antibodies in atherosclerotic cardiovascular disease	16
Epidemiology and prevention of venous thromboembolism	16
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	15
Single-cell transcriptomics for the assessment of cardiac disease	15
The dynamic cardiac cellular landscape: visualization by molecular imaging	15
Current concepts and novel targets for antiplatelet therapy	15
The microtubule cytoskeleton in cardiac mechanics and heart failure	15
Wearable blood pressure sensors for cardiovascular monitoring and machine learning algorithms for blood pressure estimation	14
Cardiac splicing as a diagnostic and therapeutic target	14
The ongoing quest for the first total artificial heart as destination therapy	14